Thomas G. Filloon

1.9k total citations · 1 hit paper
25 papers, 1.5k citations indexed

About

Thomas G. Filloon is a scholar working on Surgery, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Thomas G. Filloon has authored 25 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Physiology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Thomas G. Filloon's work include Diet and metabolism studies (5 papers), Mechanical Circulatory Support Devices (4 papers) and Gastrointestinal motility and disorders (3 papers). Thomas G. Filloon is often cited by papers focused on Diet and metabolism studies (5 papers), Mechanical Circulatory Support Devices (4 papers) and Gastrointestinal motility and disorders (3 papers). Thomas G. Filloon collaborates with scholars based in United States, Canada and Poland. Thomas G. Filloon's co-authors include R. J. Young, Robert A. Rinsky, Alexander B. Smith, Philip J. Landrigan, Richard Hornung, Andrea H. Okun, Thomas G. Todaro, Kenneth W. Mahaffey, Paul W. Armstrong and Christopher B. Granger and has published in prestigious journals such as New England Journal of Medicine, Circulation and Gastroenterology.

In The Last Decade

Thomas G. Filloon

24 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Benzene and Leukemia

1987 488 citations Robert A. Rinsky, Alexander B. Smith et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Thomas G. Filloon

Since Specialization

Citations

This map shows the geographic impact of Thomas G. Filloon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas G. Filloon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas G. Filloon more than expected).

Fields of papers citing papers by Thomas G. Filloon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas G. Filloon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas G. Filloon. The network helps show where Thomas G. Filloon may publish in the future.

Co-authorship network of co-authors of Thomas G. Filloon

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas G. Filloon. A scholar is included among the top collaborators of Thomas G. Filloon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas G. Filloon. Thomas G. Filloon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Performance Equivalence and Validation of the Soleris Automated System for Quantitative Microbial Content Testing Using Pure Suspension Cultures 2016 ·Journal of AOAC International ·Brian J. Limberg, (unknown), Thomas G. Filloon, Carl E. Catrenich	6
2	Scalp Stratum Corneum Histamine Levels: Novel Sampling Method Reveals Association with Itch Resolution in Dandruff/Seborrhoeic Dermatitis Treatment 2011 ·Acta Dermato Venereologica ·Jacek C. Szepietowski, Katharine Ker, Joseph Schwartz, Thomas G. Filloon, Angela M. Fieno, Kenneth R. Wehmeyer, Kevin J. Mills	48
3	Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health 2010 ·International Journal of Dermatology ·(unknown), (unknown), James P. Henry, Haruko Mizoguchi, James R. Schwartz, Stephen W. Morrall, Thomas G. Filloon, (unknown), Gina M. Fadayel, Kevin J. Mills	56
4	Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview 2006 ·American Heart Journal ·Kenneth W. Mahaffey, Frans Van de Werf, Stanton K. Shernan, Christopher B. Granger, Edward D. Verrier, Thomas G. Filloon, Thomas G. Todaro, Peter X. Adams, Jerrold H. Levy, Vic Hasselblad, Paul W. Armstrong	30
5	Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves 2005 ·Journal of Thoracic and Cardiovascular Surgery ·James G. Ramsay, Stanton K. Shernan, Jane C.K. Fitch, (unknown), Thomas G. Todaro, Thomas G. Filloon, Nancy A. Nussmeier	49
6	Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass 2004 ·The Annals of Thoracic Surgery ·Stanton K. Shernan, Jane C.K. Fitch, Nancy A. Nussmeier, John C. Chen, Scott A. Rollins, Christopher F. Mojcik, Kevin J. Malloy, Thomas G. Todaro, Thomas G. Filloon, Steven W. Boyce, Deepak M. Gangahar, Michael J. Goldberg, Lawrence J. Saidman, Dennis T. Mangano	81
7	Macular pigment optical density in a midwestern sample 2001 ·Ophthalmology ·Thomas A. Ciulla, (unknown), Dale A. Cooper, Billy R. Hammond, Ronald P. Danis, Linda Pratt, Karen A. Riccardi, Thomas G. Filloon	118
8	Olestra Consumption Is Not Associated with Macular Pigment Optical Density in a Cross-Sectional Volunteer Sample in Indianapolis 2000 ·Journal of Nutrition ·Dale A. Cooper, Joanne Curran‐Celentano, Thomas A. Ciulla, Billy R. Hammond, (unknown), Linda Pratt, Karen A. Riccardi, Thomas G. Filloon	17
9	Gingival crevicular fluid inflammatory mediators and bacteriology of gingivitis in nonhuman primates related to susceptibility to periodontitis 2000 ·Oral Microbiology and Immunology ·Jeffrey L. Ebersole, David Cappelli, Stanley C. Holt, R. E. Singer, Thomas G. Filloon	31
10	Effects of Olestra and Sorbitol Consumption on Objective Measures of Diarrhea: Impact of Stool Viscosity on Common Gastrointestinal Symptoms 2000 ·Regulatory Toxicology and Pharmacology ·Johnson W. McRorie, Nora L. Zorich, Karen A. Riccardi, (unknown), Thomas G. Filloon, Suman Wason, Ralph A. Giannella	33
11	Effects of Wheat Bran and Olestra on Objective Measures of Stool and Subjective Reports of Gi Symptoms 2000 ·The American Journal of Gastroenterology ·Johnson W. McRorie, (unknown), (unknown), Thomas G. Filloon, (unknown), (unknown), (unknown), Alexis Laurent, Colin D. Rudolph	20
12	A six-week randomized controlled trial of olestra or regular snack foods: Comparison of Gastro-intestinal symptoms in a large population 1998 ·Gastroenterology ·Robert S. Sandler, Nora L. Zorich, Thomas G. Filloon, (unknown), (unknown), (unknown), (unknown)	1
13	Comparison of p-fluoroketorolac and [18O3]ketorolac for use as internal standards for the determination of ketorolac by gas chromatography/mass spectrometry (GC/MS) 1998 ·Journal of Pharmaceutical and Biomedical Analysis ·Thomas H. Eichhold, Thomas G. Filloon, Kenneth R. Wehmeyer	4
14	Follow-up to the study: A randomized, double-blind, placebo-controlled consumer rechallenge test of Olean salted snacks. 1998 ·PubMed ·Nora L. Zorich, David Biedermann, Karen A. Riccardi, L J Bishop, Thomas G. Filloon	7
15	Follow-Up to the Study: A Randomized, Double-Blind, Placebo-Controlled Consumer Rechallenge Test of Olean Salted Snacks 1998 ·Regulatory Toxicology and Pharmacology ·Nora L. Zorich, David Biedermann, Karen A. Riccardi, (unknown), Thomas G. Filloon	6
16	Randomized, Double-Blind, Placebo-Controlled, Consumer Rechallenge Test of Olean Salted Snacks 1997 ·Regulatory Toxicology and Pharmacology ·Nora L. Zorich, David Biedermann, Karen A. Riccardi, (unknown), Thomas G. Filloon	13
17	ESTIMATING THE MINIMUM THERAPEUTICALLY EFFECTIVE DOSE OF A COMPOUND VIA REGRESSION MODELLING AND PERCENTILE ESTIMATION 1995 ·Statistics in Medicine ·Thomas G. Filloon	11
18	Inflammatory mediators and immunoglobulins in GCF from healthy, gingivitis and periodontitis sites 1993 ·Journal of Periodontal Research ·Jeffrey L. Ebersole, R. E. Singer, Bjorn Steffensen, Thomas G. Filloon, Kenneth S. Kornman	70
19	Benzene and Leukemia breakdown → 1987 ·New England Journal of Medicine ·Robert A. Rinsky, Alexander B. Smith, Richard Hornung, Thomas G. Filloon, R. J. Young, Andrea H. Okun, Philip J. Landrigan	488
20	NIOSH (National Institute for Occupational Safety and Health) testimony to DOL (Department of Labor) on benzene and leukemia: An epidemiologic risk assessment to the Occupational Safety and Health Administration by J. D. Millar, August 9, 1985 1985 ·OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) ·Robert A. Rinsky, Alexander B. Smith, R W Hornung, Thomas G. Filloon, R. J. Young	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact